Colan Totte.Co.,Ltd. AI Stock Analysis
Want to see JP:7792 full AI Analyst Report?
Colan Totte.Co.,Ltd. (7792) AI Stock Analysis
Colan Totte.Co.,Ltd.
(TSE/TYO:7792)
The overall score of 75 is primarily driven by exceptional financial health, highlighted by strong revenue growth and zero structural debt, alongside an attractive valuation with a low P/E and solid dividend yield. However, short-term bearish technical trends, with the stock trading below key near-term moving averages, slightly weigh down the final rating.
Colan Totte.Co.,Ltd. (7792) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 12.68B
- Dividend Yield
- 3.54%
- Average Volume (3M)
- 13.01K
- Price to Earnings (P/E)
- 8.5
- Beta (1Y)
- 0.51
- Revenue Growth
- 30.12%
- EPS Growth
- 13.38%
- Country
- Japan
- Employees
- 104
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Colan Totte.Co.,Ltd. Business Overview & Revenue Model
Company Description
Colan Totte Co., Ltd., established in Osaka, Japan, in 1997, operates as an international firm specializing in the development and global distribution of therapeutic devices under its proprietary Colantotte brand. The company's diverse product portfo...
Colan Totte.Co.,Ltd. Financial Statement Overview
Summary
Outstanding financial profile with consistent 30% top-line growth, expanding profit margins, and a pristine, debt-free balance sheet generating strong returns on equity.
Income Statement
88Very PositiveBalance Sheet
95Very PositiveCash Flow
78Positive| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.02B | 9.00B | 6.92B | 5.94B | 5.41B | 4.66B |
| Gross Profit | 5.46B | 6.30B | 4.66B | 3.97B | 3.45B | 3.04B |
| EBITDA | 2.06B | 2.35B | 1.90B | 1.57B | 1.10B | 1.02B |
| Net Income | 1.35B | 1.51B | 1.33B | 1.02B | 645.02M | 610.45M |
Balance Sheet | ||||||
| Total Assets | 7.18B | 7.92B | 6.74B | 5.43B | 4.91B | 4.13B |
| Cash, Cash Equivalents and Short-Term Investments | 2.11B | 2.50B | 2.18B | 1.76B | 1.79B | 1.34B |
| Total Debt | 8.05M | 9.67M | 12.90M | 8.69M | 1.27M | 270.48M |
| Total Liabilities | 1.62B | 1.62B | 1.57B | 1.32B | 1.64B | 1.38B |
| Stockholders Equity | 5.55B | 6.30B | 5.17B | 4.11B | 3.27B | 2.75B |
Cash Flow | ||||||
| Free Cash Flow | 1.06B | 730.15M | 728.70M | 357.26M | 867.34M | 75.48M |
| Operating Cash Flow | 1.48B | 1.19B | 998.35M | 883.77M | 955.70M | 148.09M |
| Investing Cash Flow | -471.40M | -487.70M | -303.40M | -736.91M | -83.80M | -80.38M |
| Financing Cash Flow | -654.18M | -383.00M | -272.18M | -180.15M | -410.10M | -274.23M |
Colan Totte.Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7792, the sentiment is Neutral. The current price of 1413.00 is below the 20-day moving average (MA) of 1442.75, below the 50-day MA of 1447.69, and above the 200-day MA of 1412.04, indicating a neutral trend. The MACD of -4.93 indicates Negative momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 72.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7792.
Colan Totte.Co.,Ltd. Peers Comparison
Overall Rating
JP:779275Outperform
JP:518774.3Outperform
JP:684963Neutral
JP:652361Neutral
JP:454950Neutral
JP:760045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | JPY 12.89B | 8.51 | ― | 3.54% | 30.12% | 13.38% | |
| 74Outperform | JPY 10.05B | 25.90 | ― | 4.34% | 3.38% | -52.61% | |
| 63Neutral | JPY 254.11B | 20.98 | ― | 2.06% | -0.18% | -33.38% | |
| 61Neutral | JPY 165.53B | 11.48 | 8.71% | 3.23% | 2.74% | 145.33% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | JPY 73.85B | 39.86 | ― | 2.59% | 3.92% | -52.01% | |
| 45Neutral | JPY 8.06B | -5.18 | ― | 5.56% | -8.68% | -75.03% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7792 | Colan Totte.Co.,Ltd. | 1413.00 | 8.09 | 0.58% | |
| JP:6523 | PHC Holdings Corp. | 1300.00 | 374.19 | 40.42% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2240.00 | 37.76 | 1.71% | |
| JP:5187 | Create Medic Co., Ltd. | 1105.00 | 150.20 | 15.73% | |
| JP:6849 | Nihon Kohden Corporation | 1550.00 | 20.56 | 1.34% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 306.00 | -165.73 | -35.13% |
Colan Totte.Co.,Ltd. Corporate Events
Colan Totte Reports Higher Sales, Profits and Dividend
Colan Totte Co., Ltd. is listed on the Tokyo Stock Exchange, but the release does not provide details about its industry or primary products. For the fiscal year ended September 30, 2026, the company reported net sales of ¥9,001 million, up 30.1% yea...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
